Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.

Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.

An article of manufacture is described comprising the combination of an adjunct material and a delivery particle. The delivery particle comprising a benefit agent core material and a shell encapsulating the core material is described, along with a process for forming such a delivery particle and articles of manufacture. The shell is the reaction product of: i) an isocyanate or acid chloride or acrylate with ii) an amine-containing natural material having free amino moieties, and iii) an α, β-unsaturated compound, the α, β-unsaturated compound forming C—N covalent bonds with the amine moieties of the natural material. The delivery particle of the invention has improved release characteristics, with enhanced degradation characteristics in OECD test method 301B.

The present invention relates to a new process for the preparation of microcapsules. Microcapsules obtainable by said process are also an object of the invention. Perfuming compositions and consumer products comprising said capsules, in particular perfumed consumer products in the form of home care or personal care products, are also part of the invention.

The present invention relates to a new process for the preparation of microcapsules. Microcapsules obtainable by said process are also an object of the invention. Perfuming compositions and consumer products comprising said capsules, in particular perfumed consumer products in the form of home care or personal care products, are also part of the invention.

A biomaterial including a resorbable porous matrix formed from a material including collagen, and exhibiting an inner volume and an outer surface. Advantageously, the biomaterial includes at least one type of living biological cells of a tissue, disposed in the inner volume and alternatively or complementarily on the surface of the porous matrix. The biomaterial forms a tissue substitute being close to a native tissue, in particular in terms of biological structure present in the tissue, and physiological functions.

A recombinant human type XVII collagen consists of an amino acid sequence shown in (A).sub.n or includes the amino acid sequence shown in (A).sub.n, where A is a sequence set forth in SEQ ID NO: 2, a sequence undergoing an amino acid modification to a predetermined extent based on SEQ ID NO: 2, or a sequence that has more than 80% homology with SEQ ID NO: 2; n is an integer greater than or equal to 1; and A represents a basic unit, and when there are two or more basic units, the two or more basic units are identical or different and are directly connected in tandem through a peptide bond. In the present disclosure, it is confirmed that the recombinant human type XVII collagen can undergo efficient secretory and soluble expression in eukaryotic host cells such as Pichia pastoris (P. pastoris).

Solutions containing collagen monomers and saccharides inhibit the nucleation and growth of collagen fibrils. The solutions stabilize high concentrations of soluble collagen monomers, improving their incorporation into pre-existing tissues or collagen networks, thereby providing therapeutic applications of collagen for cosmetic treatments, wound healing, and injury repair involving damaged extracellular matrix. Pharmaceutical formulations, medical devices, and kits containing the solutions are provided.

A biological function regulating agent comprises a fermented collagen peptide, and the fermented collagen peptide has at least one action selected from the group consisting of an epidermal metabolism promoting action, a fat accumulation inhibiting action, a fat decomposition promoting action and an action of regulating the amount of adipocytokine in a biological body.

Disclosed is the preparation of injectable collagen suspensions, to the method for preparing the suspensions, and to the uses thereof, particularly for forming dense collagen matrices.